Abstrakt

Przypisy

• 1. Anghelescu D.L., Goldberg J.L., Faughnan L.G., Wu J., Mao S., FurmanW.L., Santana V.M., Navid F.: Comparison of pain outcomesbetween two anti-GD2 antibodies in patients with Neuroblastoma.Pediatr. Blood Cancer, 2015; 62: 224-228
  Google Scholar
• 2. Barone G., Moreno L., Pearson A.D.: CCLG high risk neuroblastomarelapse options and pathway. Children’s Cancer and LeukaemiaGroup; www.cclg.org.uk, 2013; 19: 1-12. http://www.cclg.org.uk/publications/Treatment/Treatment-options-for-relapsed-orrefractory-high-risk-neuroblastoma/NBRELAPS
  Google Scholar
• 3. Cheng M., Ahmed M,, Xu H., Cheung N.K.: Structural design ofdisialoganglioside GD2 and CD3-bispecific antibodies to redirect Tcells for tumor therapy. Int. J. Cancer, 2015; 136: 476-486
  Google Scholar
• 4. Cheung N.K., Cheung I.Y., Kushner B.H., Ostrovnaya I., ChamberlainE., Kramer K., Modak S: Murine anti-GD2 monoclonal antibody3F8 combined with granulocyte-macrophage colony-stimulatingfactor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastomain first remission. J. Clin. Oncol., 2012; 10; 30: 3264-3270
  Google Scholar
• 5. Cheung N.K., Dyer M.A.: Neuroblastoma: developmental biology,cancer genomics and immunotherapy. Nat. Rev. Cancer, 2013;13: 397-411
  Google Scholar
• 6. Cheung N.K., Ostrovnaya I., Kuk D., Cheung I.Y.: Bone marrowminimal residual disease was an early response marker and a consistentindependent predictor of survival after anti-GD2 immunotherapy.J. Clin. Oncol., 2015; 33: 755-763
  Google Scholar
• 7. Cohn S.L., Pearson A.D., London W.B., Monclair T., Ambros P.F.,Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., Mosseri V.,Simon T., Garaventa A., Castel V., Matthay K.K.; INRG Task Force:The International Neuroblastoma Risk Group (INRG) classificationsystem: an INRG Task Force report. J. Clin. Oncol. 2009; 27: 289-297
  Google Scholar
• 8. Kushner B.H., Modak S., Basu E.M., Roberts S.S., Kramer K.,Cheung N.K.: Posterior reversible encephalopathy syndrome in neuroblastomapatients receiving anti-GD2 3F8 monoclonal antibody.Cancer, 2013; 119: 2789-2795
  Google Scholar
• 9. Kushner B.H., Ostrovnaya I., Cheung I.Y., Kuk D., Kramer K., ModakS., Yataghene K., Cheung N.V.: Prolonged progression-free survivalafter consolidating second or later remissions of neuroblastomawith Anti-GD2 immunotherapy and isotretinoin: a prospective PhaseII study. Oncoimmunology, 2015; 4: e1016704
  Google Scholar
• 10. Latorre V., Diskin S.J., Diamond M.A., Zhang H., Hakonarson H.,Maris J.M., Devoto M.: Replication of neuroblastoma SNP associationat the BARD1 locus in African-Americans. Cancer Epidemiol.Biomarkers Prev., 2012; 21: 658-663
  Google Scholar
• 11. Modak S., Kushner B.H., Kramer K., Vickers A., CheungI.Y., Cheung N.K.: Anti-GD2 antibody 3F8 and barley-derived(1→3),(1→4)-β-D-glucan: a phase I study in patients with chemoresistantneuroblastoma. Oncoimmunology, 2013; 2: e23402
  Google Scholar
• 12. Moreno L., Barone G., Park J.R., Pearson A.D.: About the benefitsof immunotherapy for high-risk Neuroblastoma. J. Clin. Oncol.,2013; 31: 649-650
  Google Scholar
• 13. Morgenstern D.A., Baruchel S., Irwin M.S.: Current and futurestrategies for relapsed neuroblastoma: challenges on the road toprecision therapy. J. Pediatr. Hematol. Oncol., 2013; 35: 337-347
  Google Scholar
• 14. Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., MattayKM, Hogarty M.: COG Neuroblastoma Committee. Children’s OncologyGroup’s 2013 blueprint for research: Neuroblastoma. Pediatr.Blood Cancer, 2013; 60: 985-993
  Google Scholar
• 15. Schulz G., Cheresh D.A., Varki N.M., Yu A., Staffileno L.K., ReisfeldR.A.: Detection of ganglioside GD2 in tumor tissues and sera ofneuroblastoma patients. Cancer Res. 1984; 44: 5914-5920
  Google Scholar
• 16. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M.,Berthold F.: No success of anti-GD2 treatment in high risk neuroblastoma?A critical appraisal. Pediatr. Blood Cancer, 2009; 53: 708.Abstract
  Google Scholar
• 17. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M.,Niethammer D., Berthold F.: Consolidation treatment with chimericanti-GD2-antibody ch14.18 in children older than 1 year with metastaticneuroblastoma. J. Clin. Oncol., 2004; 22: 3549-3557
  Google Scholar
• 18. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., KreissmanS.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., MatthayK.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A.,et al.: Children’s Oncology Group: Anti-GD2 antibody with GM-CSF,interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med.,2010; 363: 1324-1334
  Google Scholar

Pełna treść artykułu